161 related articles for article (PubMed ID: 34894701)
1. Current status of diagnosis and treatment of advanced non-small cell lung cancer in China during the COVID-19 pandemic.
Liu M; Zhao W; Li S; Chen L; Zhou C
Ann Palliat Med; 2022 Apr; 11(4):1231-1240. PubMed ID: 34894701
[TBL] [Abstract][Full Text] [Related]
2. [Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of coronavirus disease 2019 (Trial version)].
;
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Apr; 43(4):297-301. PubMed ID: 32125132
[TBL] [Abstract][Full Text] [Related]
3. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
4. [Chinese expert consensus on evaluation and treatment of advanced non-small cell lung cancer with negative driver genes after first-line immunotherapy resistance (2024 edition)].
Committee of Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):411-426. PubMed ID: 38326053
[TBL] [Abstract][Full Text] [Related]
5. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
6. Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer.
Peng S; Huang H; Chen J; Ding X; Zhu X; Liu Y; Chen L; Lu Z
Technol Cancer Res Treat; 2024; 23():15330338241248573. PubMed ID: 38656242
[No Abstract] [Full Text] [Related]
7. [Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1063-1077. PubMed ID: 33342166
[TBL] [Abstract][Full Text] [Related]
8. Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non-Small Cell Lung Cancer Versus Community Controls.
Arrato NA; Lo SB; Coker CA; Covarrubias JJ; Blevins TR; Reisinger SA; Presley CJ; Shields PG; Andersen BL
J Natl Compr Canc Netw; 2022 Feb; 20(2):118-125. PubMed ID: 35130505
[TBL] [Abstract][Full Text] [Related]
9. Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave.
Bertaglia V; Reale ML; Bironzo P; Palesandro E; Mariniello A; Leone G; Tabbò F; Bungaro M; Audisio M; Rapetti S; Di Stefano RF; Carnio S; Artusio E; Capelletto E; Sperone P; Passiglia F; Novello S
Crit Rev Oncol Hematol; 2021 Jan; 157():103189. PubMed ID: 33341505
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in non-small-cell lung cancer in China: Results from the CancerMPact survey 2020.
Durbin L; Murali B; Li S; Zhao L; Hawthorne S; Kanas G; Davis C; Clark O
Cancer Treat Res Commun; 2021; 29():100462. PubMed ID: 34583209
[TBL] [Abstract][Full Text] [Related]
11. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Perdrizet K; Leighl NB
Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
13. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
Shukla NA; Yan MN; Hanna N
Clin Lung Cancer; 2020 Jul; 21(4):308-313. PubMed ID: 32291211
[TBL] [Abstract][Full Text] [Related]
14. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
Formisano L; Jansen VM; Marciano R; Bianco R
Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress of Small Molecule Anti-angiogenic Drugs
in Non-small Cell Lung Cancer].
Dou Y; Jiang D
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):56-62. PubMed ID: 33478192
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
Song Y; Zhou Q; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Yao LD; Zhan LJ; Yang F; Wu YL
Lung Cancer; 2018 Sep; 123():7-13. PubMed ID: 30089597
[TBL] [Abstract][Full Text] [Related]
17. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
18. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
19. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
20. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
